Open AccessInteraction between the gut microbiota and oral antihyperglycemic drugs
Author(s) -
U. V. Buyvalenko,
E. V. Pokrovskaya
Publication year - 2022
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl12835
Subject(s) - gut flora , immune system , biology , microbiome , gut microbiome , drug , immunology , microbiology and biotechnology , pharmacology , bioinformatics
The gut microbiome is the largest microbial habitat in the human body. The main functions include obtaining energy from complex food fibers, maturation and formation of the immune system, intestinal angiogenesis, restoration of epithelial damage to the intestine, development of the nervous system, protection against pathogens, etc. It is also known that a number of drugs can cause changes in the composition of the intestinal microflora, and intestinal bacteria, in turn, produce a number of enzymes and metabolites that can chemically change the structure of drugs, leading to more side effects, and in some cases to positive changes. In this review we present current evidence supporting the effects of microbiota in host-drug interactions, in particular, the reciprocal effects of gut microbiota and oral hypoglycemic drugs on each other. Gaining and evaluating knowledge in this area will help pave the way for the development of new microbiota-based strategies that can be used in the future to improve treatment outcomes for type 2 diabetes mellitus (T2D).